Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COPP-ABV
- Development stage
- Phase 2
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
COPP-ABV is a combination chemotherapy regimen containing cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone, doxorubicin (Adriamycin), bleomycin, and vinblastine. This combination works by using different drugs that kill cancer cells through various mechanisms. The regimen is primarily used to treat Hodgkin lymphoma, particularly in advanced stages, and may also be effective for non-Hodgkin lymphoma. Clinical studies have shown high complete response rates, with one study reporting 83.6% complete response rate in previously untreated patients with Hodgkin's disease[2].
- Other names
- C-MOPP/ABVdCOPP-ABV
02
Targets
DNAGR (Glucocorticoid receptor)MicrotubuleMAOA (Monoamine oxidase A)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on COPP-ABV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COPP-ABV.